HRP20120085T1 - Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu - Google Patents

Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu Download PDF

Info

Publication number
HRP20120085T1
HRP20120085T1 HR20120085T HRP20120085T HRP20120085T1 HR P20120085 T1 HRP20120085 T1 HR P20120085T1 HR 20120085 T HR20120085 T HR 20120085T HR P20120085 T HRP20120085 T HR P20120085T HR P20120085 T1 HRP20120085 T1 HR P20120085T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
weight
amount
preparation according
cancer
Prior art date
Application number
HR20120085T
Other languages
English (en)
Croatian (hr)
Inventor
David Blyth John
John Day Andrew
James Lennon Kieran
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120085(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20120085T1 publication Critical patent/HRP20120085T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20120085T 2007-10-12 2008-10-09 Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu HRP20120085T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15
PCT/GB2008/050928 WO2009047565A2 (en) 2007-10-12 2008-10-09 Composition 064

Publications (1)

Publication Number Publication Date
HRP20120085T1 true HRP20120085T1 (hr) 2012-02-29

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120085T HRP20120085T1 (hr) 2007-10-12 2008-10-09 Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu

Country Status (34)

Country Link
US (2) US8168221B2 (pl)
EP (2) EP2209501B1 (pl)
JP (1) JP2011500548A (pl)
KR (1) KR20100099113A (pl)
CN (1) CN101896210A (pl)
AR (1) AR068845A1 (pl)
AT (1) ATE536893T1 (pl)
AU (1) AU2008309385B2 (pl)
BR (1) BRPI0818323A2 (pl)
CA (1) CA2701385A1 (pl)
CL (1) CL2008003022A1 (pl)
CO (1) CO6270344A2 (pl)
CR (1) CR11363A (pl)
CU (1) CU20100064A7 (pl)
CY (1) CY1112433T1 (pl)
DK (1) DK2209501T3 (pl)
DO (1) DOP2010000105A (pl)
EA (1) EA201000545A1 (pl)
ES (1) ES2377426T3 (pl)
HR (1) HRP20120085T1 (pl)
IL (1) IL204953A0 (pl)
MX (1) MX2010003989A (pl)
NI (1) NI201000052A (pl)
NZ (1) NZ585310A (pl)
PE (1) PE20091032A1 (pl)
PL (1) PL2209501T3 (pl)
PT (1) PT2209501E (pl)
SG (1) SG182138A1 (pl)
SI (1) SI2209501T1 (pl)
SV (1) SV2010003529A (pl)
TW (1) TW200924768A (pl)
UY (1) UY31385A1 (pl)
WO (1) WO2009047565A2 (pl)
ZA (1) ZA201002477B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
WO2011143347A2 (en) * 2010-05-11 2011-11-17 Sensient Colors Llc Film coating composition and methods of making and using the same
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
US20150104512A1 (en) * 2012-04-27 2015-04-16 Merck Patent Gmbh Coated tablets and the production thereof
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
HRP20200615T1 (hr) * 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
PT4331607T (pt) 2015-12-02 2025-05-22 Nippon Shinyaku Co Ltd Composição farmacêutica sólida que contém 2-{4-[n-(5,6-difenilpirazin-2-il)-n-isopropilamino]butiloxi}-n-(metil-sulfonil)acetamida
EP4129342B1 (en) * 2020-03-31 2025-10-15 Eisai R&D Management Co., Ltd. Tablet, medicine, and method and kit for manufacturing said tablet and medicine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP3455233B2 (ja) * 1997-04-28 2003-10-14 テキサス・バイオテクノロジー・コーポレイシヨン エンドテリン介在障害治療用のスルホンアミド類
CA2374760A1 (en) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
WO2003041705A1 (en) 2001-11-13 2003-05-22 Pharmacia Corporation Oral dosage form of a sulfonamide prodrug such as parecoxib
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
EP1551401A4 (en) * 2002-09-20 2006-03-22 Merck & Co Inc MANNITOL FORMULATION FOR AN INTEGRIN RECEPTOR ANTAGONIST
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
TW200924768A (en) 2007-10-12 2009-06-16 Astrazeneca Ab Composition

Also Published As

Publication number Publication date
JP2011500548A (ja) 2011-01-06
WO2009047565A2 (en) 2009-04-16
MX2010003989A (es) 2010-04-27
NZ585310A (en) 2012-02-24
IL204953A0 (en) 2010-11-30
PE20091032A1 (es) 2009-08-15
PL2209501T3 (pl) 2012-03-30
SV2010003529A (es) 2010-09-13
TW200924768A (en) 2009-06-16
DOP2010000105A (es) 2010-08-15
NI201000052A (es) 2011-03-24
WO2009047565A3 (en) 2009-11-26
ES2377426T3 (es) 2012-03-27
US20120177705A1 (en) 2012-07-12
KR20100099113A (ko) 2010-09-10
US20090099203A1 (en) 2009-04-16
AU2008309385A1 (en) 2009-04-16
EP2209501B1 (en) 2011-12-14
CU20100064A7 (es) 2011-10-05
CL2008003022A1 (es) 2010-07-23
US8168221B2 (en) 2012-05-01
EA201000545A1 (ru) 2010-10-29
EP2209501A2 (en) 2010-07-28
CO6270344A2 (es) 2011-04-20
AR068845A1 (es) 2009-12-09
CA2701385A1 (en) 2009-04-16
ATE536893T1 (de) 2011-12-15
DK2209501T3 (da) 2012-02-27
CY1112433T1 (el) 2015-12-09
UY31385A1 (es) 2009-05-29
CN101896210A (zh) 2010-11-24
PT2209501E (pt) 2012-02-03
BRPI0818323A2 (pt) 2017-05-16
HK1143095A1 (en) 2010-12-24
CR11363A (es) 2010-07-14
AU2008309385B2 (en) 2011-10-20
SG182138A1 (en) 2012-07-30
SI2209501T1 (sl) 2012-03-30
EP2433620A1 (en) 2012-03-28
ZA201002477B (en) 2010-12-29

Similar Documents

Publication Publication Date Title
HRP20120085T1 (hr) Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu
MX2010014234A (es) Compuestos pirazol 436.
MX2010005087A (es) Formulacion solida de liberacion rapida, preparacion y uso de la misma.
MY141939A (en) Pyridazine derivatives and their use as therapeutic agents
PE20061345A1 (es) Composicion farmaceutica que comprende sorafenib
HRP20170005T1 (hr) Spojevi i sastavi kao inhibitori kinaze proteina
NZ727015A (en) Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TW200801029A (en) Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
NZ702159A (en) Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
GEP20135912B (en) 1-benzyl-3- hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
PE20130657A1 (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
AR068919A1 (es) 2-[3-(2,2-difluoro-benzo[1,3]dioxol-5-ilamino)-5-(2,6-dimetil-piridin-4-il)[1,2,4]triazol-1-il]-n-etil-acetamida y analogos del mismo, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en trastornos psicoticos y/o enfermedades con dificultades intelectuales.
AR080242A1 (es) Composiciones veterinarias. usos.
MX2008011579A (es) Forma galenica divisible que permite una liberacion modificada del principio activo.
MX2010002668A (es) Una formulacion novedosa de niacina de liberacion controlada.
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
AR100977A1 (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
RU2008135718A (ru) Композиции клопидогреля бисульфата